Search Follow us

liquid biopsy

1 - 12 of 14
Sort by: popularity | newest
Page  2  of 2 | Next
NetScientific

Commercial progress across portfolio

Update | Pharmaceutical & healthcare | 15 Dec 2017

Within the month of November 2017, NetScientific portfolio companies had a series of announcements reflecting increased adoption of their products. ProAxsis announced increased sales of its research kits and guided to over GBP 1m in sales in 2018. Wanda’s partner Health Resource Solutions announced that it would be expanding the deployment of the app to all of its applicable patients. Finally, Vortex announced the first commercial sale of its VTX-1 liquid biopsy platform.

Angle

Milestone in ovarian cancer application

Flash note | Pharmaceutical & healthcare | 05 Jul 2017

This morning Angle reported initial results from its two lead clinical trials with Parsortix, a liquid biopsy system. The two studies ran in parallel in Europe (ANG-001) and the US (ANG-003) and explored Parsortix's efficacy in triaging women with ovarian masses before surgery ie looking at whether the tumour is benign or malignant to estimate the extent of the necessary surgery. Both studies recruited 200 patients each and reported sensitivity was up to 95%, while specificity was much higher than existing tests. Angle has refrained from releasing further data, as it believes that the diagnostic algorithms (combining Parsortix findings, RNA markers and patient data) that were developed during the trials could be patented.

Angle

A boost for prostate cancer indication

Flash note | Pharmaceutical & healthcare | 16 Jun 2017

Yesterday Angle announced that researchers from Queen Mary University of London's Barts Cancer Institute (BCI) published new data further supporting Angle’s Parsortix system for use in prostate cancer applications including an unexpected fundamental discovery that might ignite interest as a new research area in cancer metastasis. The study analysed blood samples from 81 prostate cancer patients and showed that Parsortix captured so-called EMTing cancer cells, those circulating tumour cells (CTCs) that are undergoing epithelial to mesenchymal transition. EMTing cells were correlated with whether the cancer became metastatic. Namely, the researchers found that EMTing cells combined with the gold standard PSA test had 92% accuracy in predicting metastasis, significantly outperforming PSA alone. The ability to capture EMTing and EMTed cells is what differentiates Parsortix from many other liquid biopsy systems. We are updating our estimates.

Angle

Data from ovarian cancer studies in Q217

ADR Outlook | Pharmaceutical & healthcare | 14 Feb 2017

Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to $175m or $23.4/ADR. The main 2017 catalysts are the results from the ovarian cancer studies; an acceleration of research use sales; any new data from Angle’s multiple KOLs and customers investigating Parsortix; and progress with the FDA analytical and clinical studies.

Angle

Data from ovarian cancer studies in Q217

Outlook | Pharmaceutical & healthcare | 14 Feb 2017

Angle’s H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle’s liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to GBP 140.3m or 188p/share. The main 2017 catalysts are the results from the ovarian cancer studies; an acceleration of research use sales; any new data from Angle’s multiple KOLs and customers investigating Parsortix; and progress with the FDA analytical and clinical studies.

NetScientific

Executive Interview - NetScientific

Edison TV: | Pharmaceutical & healthcare | 08 Nov 2016

NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board and rationalising the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in what remains of 2016 and 2017 including Series A financing for four holdings, the commercial ramp up of the Wanda digital health platform and the launch of the Vortex liquid biopsy product.

NetScientific

Transatlantic healthcare technologies

Initiation | Pharmaceutical & healthcare | 26 Aug 2016

NetScientific is a healthcare investment company with a portfolio of digital health, diagnostic, and therapeutic investees. In 2015 the company realigned its investment strategy, bringing a new highly experienced CEO on board, rationalisation of the portfolio and new funding (£18.2m gross from the issue of 15.2m new shares at 120p) to accelerate development in some of its key holdings. A series of value inflection points are expected in 2016 and 2017 including Series A financing for four holdings, the commercial ramp of the Wanda digital health platform, and the launch of the Vortex liquid biopsy product.

Angle

Progress with R&D and commercialization

ADR Update | Pharmaceutical & healthcare | 02 Aug 2016

Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercializing the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is $171m (vs $136m previously).

Angle

Progress with R&D and commercialisation

Update | Pharmaceutical & healthcare | 01 Aug 2016

Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercialising the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is £129.6m (vs £95m previously).

Sygnis

Rights issue to fund market development

Update | Pharmaceutical & healthcare | 27 Nov 2015

Sygnis sells its own-brand TruePrime and SunScript kits through its website and an international distributor network. A rights issue for €6.7m plus a €0.6m debt conversion was announced on 17 November. This will allow Sygnis to develop its brand, extend its product range of kits and enter the crucial US market. Kits may also be sold as OEM products for next-generation sequencing. A kit for cell-free DNA “liquid biopsy” analysis, a high growth area, is planned for 2016. Cash at 30 September was €0.6m with a €0.3m loan payment due by the year end.

Angle

Positive evaluations in multiple cancer types

ADR Update | Pharmaceutical & healthcare | 18 Nov 2015

Angle's proprietary cell separation system, Parsortix, can be used to capture and harvest circulating tumour cells from blood, enabling a liquid biopsy. In the near term, Parsortix is being evaluated for use in the pre-surgery triaging of ovarian masses, with a clinical study expected to commence in Q415. H215 has seen positive evaluations of Parsortix in lung, prostate and breast cancer, supporting its potential utility in the multi-billion dollar cancer care market. We value Angle at $145m.

Angle

Positive evaluations in multiple cancer types

Update | Pharmaceutical & healthcare | 18 Nov 2015

Angle's proprietary cell separation system, Parsortix, can be used to capture and harvest circulating tumour cells from blood, enabling a liquid biopsy. In the near term, Parsortix is being evaluated for use in the pre-surgery triaging of ovarian masses, with a clinical study expected to commence in Q415. H215 has seen positive evaluations of Parsortix in lung, prostate and breast cancer, supporting its potential utility in the multi-billion dollar cancer care market. We value Angle at £96m.